Related Experiment Videos
Low molecular weight heparins in clinical practice: unsolved or partially solved problems
1University of Padua Medical School, II Chair of Internal Medicine, Italy.
Archivos Del Instituto De Cardiologia De Mexico
|July 10, 1998
Summary
Low molecular weight heparins (LMWH) demonstrate efficacy comparable to standard heparin for venous thrombosis. Emerging evidence suggests LMWH
Area of Science:
- Pharmacology
- Thrombosis Research
- Medical Treatment
Background:
- Low molecular weight heparins (LMWH) are increasingly recognized for their efficacy in venous thrombosis prophylaxis and treatment, often matching standard heparin (SH).
- Despite advancements, several clinical questions regarding LMWH use remain unresolved, including side effects, application in pregnancy, and role in arterial thrombosis.
- Key areas of ongoing investigation include LMWH's potential in arterial thrombosis and suitability for home treatment or early hospital discharge of selected patients.
Purpose of the Study:
- To review the current status and unresolved issues concerning the use of low molecular weight heparins (LMWH) in thrombotic disease management.
- To highlight the evolving role of LMWH in both venous and arterial thrombosis.
- To assess the feasibility and implications of home treatment or early discharge protocols using LMWH.
Main Methods:
- Literature review of recent studies on low molecular weight heparins (LMWH).
- Analysis of clinical data pertaining to LMWH efficacy, safety, and specific indications.
- Synthesis of findings related to unresolved issues such as side effects, pregnancy use, arterial thrombosis, and treatment settings.
Main Results:
- LMWH show comparable effectiveness to standard heparin (SH) in venous thrombosis prophylaxis and treatment.
- Evidence suggests LMWH may be beneficial in managing arterial thrombotic events, including coronary disease and ischemic stroke.
- Recent studies support the use of LMWH for home treatment or early hospital discharge in selected patients with venous thromboembolism.
Conclusions:
- Low molecular weight heparins (LMWH) represent significant progress in the management and prophylaxis of thrombotic diseases.
- Further research is warranted to address remaining uncertainties regarding LMWH, such as standardization and long-term effects.
- The expanding applications of LMWH, particularly in arterial thrombosis and outpatient settings, underscore their therapeutic importance.